Non-intense CD13 and CD33 expression was observed in 16.7% of B-ALL cases including 12.5 and 18.7% of MOP+ve cases, and 18.2 and 15.9% of MOP-ve cases respectively. This evidence concerns the gene ANPEP and precursor B-cell acute lymphoblastic leukemia.